"If you go out in the woods today,
You'd better not go alone.
It's lovely out in the woods today,
But safer to stay at home. " Teddy Bear's Picnic, J.Kennedy
hard to find a healthcare stock where there is such a wide divergence
of opinion and range of possible outcomes as with Forest Labs (FRX).
Despite an exemplary record of free cash flow production and sales
execution, many analysts still cannot find the will to believe that the
company can reload after the loss of Lexapro and resume a growth
trajectory. While there are in fact good reasons to wonder about the
future growth of the company, this is a story where the courageous could
come out with sizable capital gains.
Please follow this link for the full article:
Plenty Of Analysts Scared To Go Into Forest Labs